{"id":11386,"date":"2026-02-12T17:56:34","date_gmt":"2026-02-12T17:56:34","guid":{"rendered":"https:\/\/medical-article.com\/?p=11386"},"modified":"2026-02-12T17:56:34","modified_gmt":"2026-02-12T17:56:34","slug":"addressing-the-translational-research-gap","status":"publish","type":"post","link":"https:\/\/medical-article.com\/?p=11386","title":{"rendered":"Addressing the translational research gap"},"content":{"rendered":"

In a recent report<\/a>, the Association of the British Pharmaceutical Industry (ABPI) examines the UK\u2019s \u201ctranslational readiness gap\u201d\u2014the persistent failure to move cutting-edge laboratory models into the actual creation of medicines to treat patients.<\/p>\n

The Attrition Problem and the Translational Gap<\/h3>\n

Modern drug development is a high risk endeavor. Approximately 90% of drug candidates that enter clinical trials fail to reach the market. What can be done about this? Can new technology\u2013including AI\u2013help increase the success rate?<\/p>\n

UK academics have pioneered \u201chuman-relevant\u201d models\u2014technologies like organ-on-a-chip, 3D bioprinting, and advanced computer simulations (in silico models) that aim to mimic human systems more accurately. In the US, NIH announced launch of the Standardized Organoid Modeling Center<\/a> at the Frederick National Laboratory for Cancer Research. In Europe, imSAVAR<\/a> project aims to deliver human-relevant models to improve the efficacy and safety testing of immunomodulatory therapies. However, the ABPI identifies a massive \u201ctranslational readiness gap\u201d from these initiatives. While these models are scientifically brilliant, are they able to be translated into real-world drug discoveries? An ABPI report identifies key gaps and limitations that impede the ability to leverage these scientific discoveries and turn them into treatments that help real-world patients. Current gaps and limitations identified by ABPI include:<\/p>\n

Principal Gaps and Limitations<\/h3>\n

1. Materials and biological inputs<\/strong><\/p>\n

Cell sourcing and characterisation.<\/strong>\u00a0Limited availability of well characterised, quality controlled cell sources; choices often driven by availability rather than fitness for purpose.Stem cell expertise and maturity.<\/strong>\u00a0Technical challenges in differentiation\/maturation of induced pluripotent stem cell (iPSC) derived cells (immaturity undermines physiological relevance).Standardisation of patient derived samples.<\/strong>\u00a0Variable collection, processing and storage practices reduce reproducibility and comparability. Consent processes and commercial use permissions are inconsistently applied.Linked clinical data.<\/strong>\u00a0Fragmented ability to connect biological samples with associated clinical data across biobanks limits stratification and validation.<\/p>\n

2. Scientific and technical limitations<\/strong><\/p>\n

Lack of standardisation.<\/strong>\u00a0No sector wide \u2018gold standards\u2019 or harmonised protocols for many\u00a0in vitro<\/em>\u00a0systems; inconsistent endpoints and assay conditions hinder comparison.Physiological complexity.\u00a0<\/strong>Key biological features remain difficult to model reliably \u2013 notably functional vasculature and robust blood brain barrier systems.Tissue microenvironment and multi organ modelling.<\/strong>\u00a0Challenges integrating extracellular matrices, mechanical cues and multi tissue interactions constrain systemic modelling of medicine effects.Confidence and regulatory acceptance.\u00a0<\/strong>Limited comparative data versus pre-clinical\/clinical datasets reduces confidence among industry and regulators.Regulatory landscape.<\/strong>\u00a0International regulators show growing interest, but regulatory qualification and acceptance for in vitro approaches remain limited and require clear validation and context of use definitions.<\/p>\n

3. Infrastructure, funding and skills<\/strong><\/p>\n

Translational pull-through.<\/strong>\u00a0There is limited support for models developed in academia to be further developed for their use in pharmaceutical research.Biobank resourcing.<\/strong>\u00a0High costs of storing samples and managing linked data are bottlenecks for national biobanking capacity.Fragmentation and lack of connectivity.<\/strong>\u00a0Expertise is geographically and institutionally siloed, limiting coordinated development and standardisation.Skills gap.<\/strong>\u00a0There is inadequate distributed training in stem cell techniques, bioengineering, multi modal assay development and data analytics needed to translate complex models.<\/p>\n

Closing the Gap<\/h3>\n

To address this issue, the 2025 Life Sciences Sector Plan (LSSP)<\/a> announced the establishment of a pre-clinical translational models hub, bringing together cutting-edge human disease modelling capabilities and essential data. ABPI argues that pharmaceutical firms should be involved earlier on in these initiatives to increase the likelihood that science moves to medicines more rapidly. They write: \u201cRealising the full potential of these models for pharmaceutical R&D will require targeted investment in infrastructure and a coordinated national strategy to support model validation, translation and cross-sector collaboration.\u201d <\/p>\n

ABPI argues that by involving pharmaceutical companies early in the design phase, the UK can ensure that the next generation of models is built with the standardization, scalability, and regulatory data required to finally lower the 90% attrition rate and bring safer medicines to patients faster.<\/p>\n

Bringing academia and industry together to address the identified gaps has the potential to be highly promising. The key would be figuring out the specifics to make this promise a reality.<\/p>","protected":false},"excerpt":{"rendered":"

In a recent report, the Association of the British Pharmaceutical Industry (ABPI) examines the UK\u2019s \u201ctranslational readiness gap\u201d\u2014the persistent failure to move cutting-edge laboratory models into the actual creation of medicines to treat patients. The Attrition Problem and the Translational Gap Modern drug development is a high risk endeavor. Approximately 90% of drug candidates that…<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-11386","post","type-post","status-publish","format-standard","hentry","category-articles"],"_links":{"self":[{"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/posts\/11386"}],"collection":[{"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/medical-article.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11386"}],"version-history":[{"count":0,"href":"https:\/\/medical-article.com\/index.php?rest_route=\/wp\/v2\/posts\/11386\/revisions"}],"wp:attachment":[{"href":"https:\/\/medical-article.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medical-article.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medical-article.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}